Shaping the Future of Digital Health: Join the 2025 Digital Healthcare Industry Matchmaking Conference!

Digital health is reshaping healthcare scenarios at an unprecedented pace.

Taking the detection end as an example, simply “brushing your teeth” enables a comprehensive oral examination, allowing physicians to obtain accurate true-color digital impressions and visualized oral examination reports within minutes. At the diagnosis and treatment end, 5G-enabled ultra-high-definition video consultations effectively “bring” operating rooms from top-tier (Grade A tertiary) hospitals to county-level facilities, enabling patients at the grassroots level to receive real-time guidance from leading experts without leaving their counties. Finally, at the rehabilitation end, wearable devices continuously collect patient data such as joint range of motion and muscle strength, providing movement correction and training feedback to achieve remote and precision rehabilitation.

In fact, this is only the beginning. As relevant policies are further implemented and innovative technologies such as 5G, AI, and big data become more deeply integrated into healthcare scenarios, the next phase of digital health will unlock even greater possibilities.

To this end, at the “4th Global Digital Trade Expo” (hereinafter referred to as the “Digital Trade Expo”) held from September 25 to 29, 2025, digital healthcare once again became the focal point of the industry,The “Digital Healthcare Industry Matchmaking Conference and Related Events” (hereinafter referred to as the “Matchmaking Conference”), themed “Digital Healthcare, Global Sharing,” is scheduled to take place on September 25–26 and serves as one of the key events of the Digital Trade Fair.。

It is reported that the “Matchmaking Conference” was hosted by the Organizing Committee of the Global Digital Trade Expo, and undertaken by the Hangzhou Municipal People’s Government, the Provincial Department of Commerce, the Provincial Health Commission, the Provincial Department of Economy and Information Technology, the Provincial Department of Science and Technology, the Provincial Healthcare Security Administration, the Provincial Medical Products Administration, and the China Association of Enterprises with Foreign Investment. The People’s Government of Gongshu District, Hangzhou, and the Professional Committee on Digital Healthcare Industry served as the executive units. As the chair entity of the Professional Committee on Digital Healthcare Industry, AstraZeneca was invited to participate and collaborate in promoting multidimensional innovation, helping to gather industrial ecosystem resources from government, industry, academia, research, healthcare, and investment sectors. Together, they continuously explore new technologies, new business formats, and new models in the digital healthcare industry, thereby facilitating the high-level development of a premier hub for the digital healthcare industry.

According to the "2025-2030 China Digital Healthcare Industry Market Research and Investment Prospect Forecast Report" released by the China Business Industry Research Institute,The market size of China's digital health comprehensive service industry has grown from RMB 76.4 billion in 2020 to RMB 220.3 billion in 2024, with a five-year compound annual growth rate (CAGR) of 30.31%.. It is projected that by 2030, the market size of China's digital healthcare industry will surpass the RMB 500 billion mark.

This is undoubtedly a market with immense potential, driven by the dual forces of policy support and clinical demand. On one hand, with the in-depth implementation of the “Healthy China 2030” strategy and the accelerating integration of the global digital health industry, digital healthcare has become a key force in promoting the balanced allocation of medical resources and achieving universal health coverage. On the other hand, an aging population, an increasing burden of chronic diseases, and growing public demand for precise and personalized diagnosis and treatment services are continuously straining traditional healthcare systems. Digital healthcare, leveraging innovative technologies such as 5G, AI, and big data, transforms high-quality medical resources into reusable and scalable algorithms and models, thereby effectively bridging this supply-demand gap.

Thus, an industrial transformation aimed at building a new digital healthcare ecosystem is rapidly unfolding, with its primary focus on specialization, internationalization, digitization, and whole-chain integration—precisely the core themes of this “Matchmaking Conference.”

Specifically,At the level of specialization, the primary focus is on promoting industry standards and certification procedures for digital healthcare, thereby enhancing the quality and safety of medical services in China.To this end, the “Matchmaking Session” specially invited multiple functional departments to participate, aiming to promote industry standards and certification for digital healthcare, enhance the professionalism of digital healthcare services, strengthen big data mining in healthcare, provide personalized and precise medical services, accelerate the promotion and application of digital medical devices, and effectively improve the quality and safety of medical services in China. In addition, the conference established a “Government-Enterprise Matchmaking Session” to facilitate face-to-face communication between government officials and enterprises, clarify the pain points and needs of the digital healthcare industry, and thereby formulate more precise and effective policy measures.

Secondly, at the international level, the “Matchmaking Conference” specially invited global pharmaceutical and medical device leaders such as AstraZeneca, Medtronic, Danaher, and Johnson & Johnson to participate deeply, promoting multi-dimensional cooperation with local digital health innovators and institutions., while enhancing the international visibility of domestic digital health products, also accelerating the global implementation of Chinese digital health solutions, thereby achieving bidirectional empowerment through both “bringing in” and “going global.”

Subsequently, at the digital level, accelerate the integration of innovative technologies with a broader range of healthcare scenarios to enhance the market accessibility and service efficiency of digital health.As planned in the agenda, this “Matchmaking Meeting” will feature thematic discussions on the digital applications across multiple clinical scenarios. Centering on the closed-loop implementation of “digital screening – intelligent diagnosis – precision treatment – full-cycle management,” the event aims to further unlock the multiplier effect of data elements throughout the entire healthcare value chain. Concurrently, the “Digital Healthcare Exhibition Zone” will showcase groundbreaking products that highlight cutting-edge trends in medical technology, offering attendees an up-close experience of future application scenarios in digital healthcare.

Finally, at the full-chain level, a complete digital health ecosystem is formed by integrating the upstream and downstream segments of the digital health industry chain.In fact, digital healthcare is a systematic endeavor that requires the deep involvement of multiple stakeholders, including clinicians, research experts, leading enterprises, and government agencies. The “Matchmaking Conference” essentially builds a bridge for direct communication among these parties. Through thematic activities, roundtable discussions, government-enterprise matchmaking sessions, and exhibition zones, it facilitates the alignment and integration of high-quality resources, thereby promoting the high-quality development of the digital healthcare industry.

It is evident that digital healthcare is currently accelerating along the fast track of industrial development, and the “Matchmaking Event” will serve as an accelerator to amplify this momentum.

This year marks AstraZeneca’s fourth consecutive year of participation in the Global Digital Trade Expo., over the past three conferences, AstraZeneca has leveraged its extensive expertise in the integration of digitalization and healthcare to drive the implementation of multiple innovative digital health diagnostic and therapeutic solutions. In collaboration with a diverse range of partners from government, industry, academia, research institutions, healthcare providers, and investment sectors, it has jointly built a future-oriented digital health ecosystem.

In fact, as one of the first multinational pharmaceutical companies in China to focus on digital health, AstraZeneca has been deeply committed to advancing the development and ecosystem building of China’s digital health industry. It has taken the lead in collaborating with ecosystem partners to introduce innovative models—such as AI-assisted diagnosis, internet hospitals, and smart chronic disease management—into practice, dedicated to transforming diagnosis and treatment to benefit more patients.

Therefore, at this Global Digital Trade Expo (GDTE), as the chair entity of the GDTE’s Digital Healthcare Professional Committee (hereinafter referred to as the “Specialized Committee”), AstraZeneca will further amplify its value, collaborate with ecosystem partners to drive multidimensional innovation, and explore greater future possibilities for the digital healthcare industry.

· Multiple Major Breakthroughs Unveiled, Ushering in a New Era of Digital Healthcare

AstraZeneca presented its practices and achievements in leveraging digital intelligence to transform diagnosis and treatment through collaboration across government, industry, academia, research, healthcare, and investment sectors. These efforts include projects such as the Standardized Metabolic Disease Management Centers (MMC) and Breast Cancer Care Excellence (BCCE) centers, which AstraZeneca has supported in establishing. Additionally, at the Digital Trade Fair exhibition booth, AstraZeneca debuted its “AI Efficiency Enhancement Zone,” showcasing interactive experiences featuring devices and technologies from AstraZeneca and its deep-tier partners. Examples included AI-assisted pulmonary function testing glasses and AI-powered literature tools, among other digital solutions designed to promote standardized clinical practice and improve operational efficiency.

· Partnering with leading AI enterprises to empower the digital transformation and upgrading of the healthcare industry

Since 2024, AstraZeneca has successively announced the upgrade of its Shanghai R&D Center into a Global Strategic R&D Center and the establishment of its sixth global—and second in China—Strategic R&D Center in Beijing, underscoring the company’s confidence in China’s life sciences innovation ecosystem. Notably, the Beijing Strategic R&D Center will leverage China’s strengths in cutting-edge biology and artificial intelligence to accelerate new drug development, thereby benefiting more patients.Evinova, the independent health tech business operator under its umbrella, will also make an appearance., this initiative will be deeply embedded in China’s digital healthcare landscape, accelerating its evolution from “isolated tools” to a “comprehensive leap.” At the matchmaking session, numerous participating experts jointly explored how to better leverage AI technologies to empower and optimize clinical trial design and delivery, accelerate pharmaceutical and medical device development, reduce costs, and improve patient experience.

·Partnering with ecosystem collaborators to drive further innovation in digital health

As the chairing organization of the special committee, AstraZeneca has been committed to aggregating industrial ecosystem resources—including research universities, leading enterprises, and capital—to foster closer and deeper connections and collaborations, while continuously exploring industry innovation and ecosystem development. At this collaborative innovation roadshow themed “Biotechnology · Digital Health,” AstraZeneca will invite over 30 investors from various sectors to participate. This initiative aims to jointly discuss growth pathways for projects while facilitating in-depth cooperation between the projects and stakeholders across the industry chain, thereby accelerating the global launch of more cutting-edge products.

In fact, participation in the Global Digital Trade Expo is just one step in AstraZeneca’s continued investment in the digital healthcare ecosystem. Looking ahead, AstraZeneca will further expand its empowerment efforts to benefit more patients in China and make high-quality digital healthcare resources readily accessible.

Currently, digital healthcare stands at a critical juncture of industrial transformation, poised to usher in a new wave of development opportunities. To maximize its industrial momentum and facilitate the implementation of more innovative digital healthcare achievements, deeper collaboration and integration are required among governments, medical institutions, research institutes, innovative enterprises, and investors.

This is precisely the raison d'être of the Global Digital Trade Expo (GDTE). In addition to hosting the “Digital Healthcare Industry Matchmaking Conference and Related Activities,” the event concurrently features exhibition zones, collaborative innovation roadshows themed “Biotechnology · Digital Health,” and multiple special forums on digital healthcare. These initiatives aim to foster deeper connections and co-create value among stakeholders from academia, research institutions, industry, healthcare providers, and investment sectors.

This concerns every stakeholder in the digital health ecosystem. To this end, we sincerely invite all peers to join us in becoming participants and witnesses to the industrial upgrade and transformation of digital healthcare.

September 25–29, 2025, Hangzhou, China. See you there!

(Registration QR Code)

Approval No.: CN-168329

Valid until: 2025-09-30

Note: All materials in this article are provided by AstraZeneca and are intended solely for conference promotional purposes.